These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32670175)

  • 1. Epidemiology of Pediatric NMOSD in Germany and Austria.
    Lechner C; Breu M; Wendel EM; Kornek B; Schanda K; Baumann M; Reindl M; Rostásy K
    Front Neurol; 2020; 11():415. PubMed ID: 32670175
    [No Abstract]   [Full Text] [Related]  

  • 2. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide.
    Hor JY; Asgari N; Nakashima I; Broadley SA; Leite MI; Kissani N; Jacob A; Marignier R; Weinshenker BG; Paul F; Pittock SJ; Palace J; Wingerchuk DM; Behne JM; Yeaman MR; Fujihara K
    Front Neurol; 2020; 11():501. PubMed ID: 32670177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuromyelitis optica spectrum disorders: A nationwide Portuguese clinical epidemiological study.
    Santos E; Rocha AL; Oliveira V; Ferro D; Samões R; Sousa AP; Figueiroa S; Mendonça T; Abreu P; Guimarães J; Sousa R; Melo C; Correia I; Durães J; Sousa L; Ferreira J; de Sá J; Sousa F; Sequeira M; Correia AS; André AL; Basílio C; Arenga M; Mendes I; Marques IB; Perdigão S; Felgueiras H; Alves I; Correia F; Barroso C; Morganho A; Carmona C; Palavra F; Santos M; Salgado V; Palos A; Nzwalo H; Timóteo A; Guerreiro R; Isidoro L; Boleixa D; Carneiro P; Neves E; Silva AM; Gonçalves G; Leite MI; Sá MJ
    Mult Scler Relat Disord; 2021 Nov; 56():103258. PubMed ID: 34583213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The occurrence of myelin oligodendrocyte glycoprotein antibodies in aquaporin-4-antibody seronegative Neuromyelitis Optica Spectrum Disorder: A systematic review and meta-analysis.
    Li X; Zhang C; Jia D; Fan M; Li T; Tian DC; Liu Y; Shi FD
    Mult Scler Relat Disord; 2021 Aug; 53():103030. PubMed ID: 34118585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.
    Ungureanu A; de Seze J; Ahle G; Sellal F
    Rev Neurol (Paris); 2018 Dec; 174(10):675-679. PubMed ID: 30293882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Seroprevalence of MOG and AQP4 Antibodies and Outcomes in an Indian Cohort of Pediatric Acquired Demyelinating Syndromes.
    Sankhyan N; Rawat A; Vyas S; Sahu JK; Bhagwat C; Madaan P; Saini L; Saini AG; Suthar R; Sukhija J; Jayashree M
    Neuropediatrics; 2022 Oct; 53(5):351-357. PubMed ID: 35617966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype.
    Kitley J; Woodhall M; Waters P; Leite MI; Devenney E; Craig J; Palace J; Vincent A
    Neurology; 2012 Sep; 79(12):1273-7. PubMed ID: 22914827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands.
    van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ
    Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Argonaute antibodies as a potential biomarker in NMOSD.
    Carta S; Le Duy D; Rogemond V; Derache N; Chaumont H; Fromont A; Cabasson S; Boudot de la Motte M; Honnorat J; Marignier R
    J Neurol Neurosurg Psychiatry; 2023 Sep; 94(9):738-741. PubMed ID: 36810322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.
    de Seze J
    Curr Opin Neurol; 2019 Feb; 32(1):111-114. PubMed ID: 30562266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical analysis of neuromyelitis optica spectrum disorders in childhood].
    Zhou J; Zhang Y; Ji TY; Jin YW; Bao XH; Zhang YH; Xiong H; Chang XZ; Jiang YW; Wu Y
    Zhonghua Er Ke Za Zhi; 2019 Feb; 57(2):118-124. PubMed ID: 30695886
    [No Abstract]   [Full Text] [Related]  

  • 15. Pediatric neuromyelitis optica spectrum disorders in Portugal: A multicentre retrospective study.
    Martins C; Moura J; Figueiroa S; Garrido C; Martins J; Samões R; Guimarães J; Melo C; Sousa R; Palavra F; Ferreira J; da Silva AM; Sá MJ; Santos E
    Mult Scler Relat Disord; 2022 Mar; 59():103531. PubMed ID: 35078127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric Neuromyelitis Optica Spectrum Disorders.
    Gombolay GY; Chitnis T
    Curr Treat Options Neurol; 2018 May; 20(6):19. PubMed ID: 29721683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
    Havla J; Kümpfel T; Schinner R; Spadaro M; Schuh E; Meinl E; Hohlfeld R; Outteryck O
    J Neurol; 2017 Jan; 264(1):139-151. PubMed ID: 27844165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes.
    Alves Do Rego C; Collongues N
    Rev Neurol (Paris); 2018 Jun; 174(6):458-470. PubMed ID: 29685427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.